双期增强CT鉴别乏脂性腺瘤与嗜铬细胞瘤
回顾性纳入132个乏脂性腺瘤和97个嗜铬细胞瘤,双期增强CT定量与定性特征比较显示嗜铬细胞瘤平扫及动静脉期CT值更高、强化率更低。多因素分析确定大小>29 mm、动脉期CT值>81 HU、静脉期CT值>97 HU、静脉期强化率≤1.5及囊变是嗜铬细胞瘤危险因素,诊断评分模型AUC为0.911。
要点
- 嗜铬细胞瘤较乏脂性腺瘤更大且更易囊变(p<0.01)
- 嗜铬细胞瘤平扫、动脉期及静脉期CT值均高于乏脂性腺瘤(均p<0.05)
- 嗜铬细胞瘤动脉期及静脉期强化率均低于乏脂性腺瘤(均p<0.05)
核心结论
- 双期增强CT在鉴别乏脂性腺瘤与嗜铬细胞瘤方面显示出良好的诊断性能,诊断评分模型AUC为0.911。
研究设计与样本
- 回顾性研究,纳入129例患者共132个乏脂性腺瘤和93例患者共97个嗜铬细胞瘤,均经病理证实;行腹部平扫及动脉期、静脉期双期增强CT;采用单因素分析比较两组定量和定性影像特征,多因素logistic回归分析评估嗜铬细胞瘤危险因素,并基于危险因素的比值比(OR)建立诊断评分模型。
关键影像表现/征象
- 嗜铬细胞瘤较乏脂性腺瘤更大且更常出现囊变(p<0.01)
- 两组峰值强化期无显著差异(p=0.348)
- 嗜铬细胞瘤平扫CT值(CTU)、动脉期CT值(CTA)和静脉期CT值(CTV)均显著高于乏脂性腺瘤(均p<0.05)
- 嗜铬细胞瘤动脉期强化率(ERA)和静脉期强化率(ERV)均显著低于乏脂性腺瘤(均p<0.05)
诊断标准与关键数值
- 多因素分析显示病灶大小>29 mm为嗜铬细胞瘤危险因素(OR=5.74,95%CI 2.51-13.16,p<0.001)
- 动脉期CT值>81 HU为嗜铬细胞瘤危险因素(OR=2.54,95%CI 1.04-6.17,p=0.04)
- 静脉期CT值>97 HU为嗜铬细胞瘤危险因素(OR=11.19,95%CI 3.21-38.97,p<0.001)
- 静脉期强化率≤1.5为嗜铬细胞瘤危险因素(OR=20.23,95%CI 6.30-64.87,p<0.001)
- 存在囊变为嗜铬细胞瘤危险因素(OR=6.22,95%CI 1.74-22.25,p=0.005)
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the diagnostic performance of biphasic contrast-enhanced CT in differentiation of lipid-poor adenomas from pheochromocytomas.
METHODS: 129 patients with 132 lipid-poor adenomas and 93 patients with 97 pheochromocytomas confirmed by pathology were included in this retrospective study. Patients underwent unenhanced abdominal CT scan followed by arterial and venous phase. Quantitative and qualitative imaging features were compared between the two groups using univariate analysis. Risk factors for pheochromocytomas were evaluated by multivariate logistic regression analysis and a diagnostic scoring model was established based on odd ratio (OR) of the risk factors.
RESULTS: Pheochromocytomas were larger and showed cystic degeneration more frequently compared with lipid-poor adenomas (p < 0.01). No significant difference was found in peak enhancement phase between the two groups (p = 0.348). Attenuation values on unenhanced phase (CTU), arterial phase (CTA), and venous phase (CTV) of pheochromocytomas were significantly higher than that of lipid-poor adenomas while enhancement ratio on arterial and venous phase (ERA, ERV) of pheochromocytomas was significantly lower than that of lipid-poor adenomas (all p < 0.05). Multivariate analysis revealed lesion size > 29 mm (OR: 5.74; 95% CI 2.51-13.16; p < 0.001), CTA > 81 HU (OR: 2.54; 95% CI 1.04-6.17; p = 0.04), CTV > 97 HU (OR: 11.19; 95% CI 3.21-38.97; p < 0.001), ERV ≤ 1.5 (OR: 20.23; 95% CI 6.30-64.87; p < 0.001), and the presence of cystic degeneration (OR: 6.22, 95% CI 1.74-22.25; p = 0.005) were risk factors for pheochromocytomas. The diagnostic scoring model yielded an area under the curve (AUC) of 0.911.
CONCLUSIONS: Biphasic contrast-enhanced CT showed good diagnostic performance in differentiation of lipid-poor adenomas from pheochromocytomas.
引用
- An YY, Yang GZ, Lin B, et al. Differentiation of lipid-poor adenoma from pheochromocytoma on biphasic contrast-enhanced CT. Abdom Radiol (NY). 2021. PMID: 34036424. doi:10.1007/s00261-021-03121-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。